000127097 001__ 127097
000127097 005__ 20240228140906.0
000127097 0247_ $$2doi$$a10.1158/1078-0432.CCR-14-1324
000127097 0247_ $$2pmid$$apmid:25336695
000127097 0247_ $$2ISSN$$a1078-0432
000127097 0247_ $$2ISSN$$a1557-3265
000127097 0247_ $$2altmetric$$aaltmetric:2802351
000127097 037__ $$aDKFZ-2017-03123
000127097 041__ $$aeng
000127097 082__ $$a610
000127097 1001_ $$aMerino, Diana M$$b0
000127097 245__ $$aMolecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups.
000127097 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2015
000127097 3367_ $$2DRIVER$$aarticle
000127097 3367_ $$2DataCite$$aOutput Types/Journal article
000127097 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1508837368_29222
000127097 3367_ $$2BibTeX$$aARTICLE
000127097 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127097 3367_ $$00$$2EndNote$$aJournal Article
000127097 520__ $$aTo investigate molecular alterations in choroid plexus tumors (CPT) using a genome-wide high-throughput approach to identify diagnostic and prognostic signatures that will refine tumor stratification and guide therapeutic options.One hundred CPTs were obtained from a multi-institutional tissue and clinical database. Copy-number (CN), DNA methylation, and gene expression signatures were assessed for 74, 36, and 40 samples, respectively. Molecular subgroups were correlated with clinical parameters and outcomes.Unique molecular signatures distinguished choroid plexus carcinomas (CPC) from choroid plexus papillomas (CPP) and atypical choroid plexus papillomas (aCPP); however, no significantly distinct molecular alterations between CPPs and aCPPs were observed. Allele-specific CN analysis of CPCs revealed two novel subgroups according to DNA content: hypodiploid and hyperdiploid CPCs. Hyperdiploid CPCs exhibited recurrent acquired uniparental disomy events. Somatic mutations in TP53 were observed in 60% of CPCs. Investigating the number of mutated copies of p53 per sample revealed a high-risk group of patients with CPC carrying two copies of mutant p53, who exhibited poor 5-year event-free (EFS) and overall survival (OS) compared with patients with CPC carrying one copy of mutant p53 (OS: 14.3%, 95% confidence interval, 0.71%-46.5% vs. 66.7%, 28.2%-87.8%, respectively, P = 0.04; EFS: 0% vs. 44.4%, 13.6%-71.9%, respectively, P = 0.03). CPPs and aCPPs exhibited favorable survival.Our data demonstrate that differences in CN, gene expression, and DNA methylation signatures distinguish CPCs from CPPs and aCPPs; however, molecular similarities among the papillomas suggest that these two histologic subgroups are indeed a single molecular entity. A greater number of copies of mutated TP53 were significantly associated to increased tumor aggressiveness and a worse survival outcome in CPCs. Collectively, these findings will facilitate stratified approaches to the clinical management of CPTs.
000127097 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000127097 588__ $$aDataset connected to CrossRef, PubMed,
000127097 650_7 $$2NLM Chemicals$$aNeoplasm Proteins
000127097 650_7 $$2NLM Chemicals$$aTP53 protein, human
000127097 650_7 $$2NLM Chemicals$$aTumor Suppressor Protein p53
000127097 7001_ $$aShlien, Adam$$b1
000127097 7001_ $$aVillani, Anita$$b2
000127097 7001_ $$aPienkowska, Malgorzata$$b3
000127097 7001_ $$aMack, Stephen$$b4
000127097 7001_ $$aRamaswamy, Vijay$$b5
000127097 7001_ $$aShih, David$$b6
000127097 7001_ $$aTatevossian, Ruth$$b7
000127097 7001_ $$aNovokmet, Ana$$b8
000127097 7001_ $$aChoufani, Sanaa$$b9
000127097 7001_ $$aDvir, Rina$$b10
000127097 7001_ $$aBen-Arush, Myran$$b11
000127097 7001_ $$aHarris, Brent T$$b12
000127097 7001_ $$aHwang, Eugene I$$b13
000127097 7001_ $$aLulla, Rishi$$b14
000127097 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b15$$udkfz
000127097 7001_ $$aAchatz, Maria Isabel$$b16
000127097 7001_ $$aJabado, Nada$$b17
000127097 7001_ $$aFinlay, Jonathan L$$b18
000127097 7001_ $$aWeksberg, Rosanna$$b19
000127097 7001_ $$aBouffet, Eric$$b20
000127097 7001_ $$aHawkins, Cynthia$$b21
000127097 7001_ $$aTaylor, Michael D$$b22
000127097 7001_ $$aTabori, Uri$$b23
000127097 7001_ $$aEllison, David W$$b24
000127097 7001_ $$aGilbertson, Richard J$$b25
000127097 7001_ $$aMalkin, David$$b26
000127097 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-14-1324$$gVol. 21, no. 1, p. 184 - 192$$n1$$p184 - 192$$tClinical cancer research$$v21$$x1557-3265$$y2015
000127097 909CO $$ooai:inrepo02.dkfz.de:127097$$pVDB
000127097 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000127097 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000127097 9141_ $$y2015
000127097 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2015
000127097 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127097 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127097 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127097 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127097 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127097 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127097 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127097 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127097 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127097 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CANCER RES : 2015
000127097 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000127097 980__ $$ajournal
000127097 980__ $$aVDB
000127097 980__ $$aI:(DE-He78)B062-20160331
000127097 980__ $$aUNRESTRICTED